Tweet
JANUARY 27, 202111:41 PM UPDATED 6 HOURS AGO
By Sangmi Cha
SEOUL (Reuters) - South Korea will review the use of AstraZeneca’s COVID-19 vaccine for the elderly because of limited efficacy data, the government said on Thursday, as it unveiled a plan to inoculate 10 million high-risk people by July.
... a review was under way by the Ministry of Food and Drug Safety, together with an independent advisory board, on whether to use the AstraZeneca vaccine for those over the age of 65.
“There is an insufficient number of test cases of elderly people in the clinical test data that have been submitted so we need a statistical review,” ministry official Kim Sang-bong told the briefing.
AstraZeneca denied media reports this week that its vaccine was not very effective for people over 65, saying a strong immune response to the vaccine had been shown in blood analysis of elderly trial participants.
By Sangmi Cha
SEOUL (Reuters) - South Korea will review the use of AstraZeneca’s COVID-19 vaccine for the elderly because of limited efficacy data, the government said on Thursday, as it unveiled a plan to inoculate 10 million high-risk people by July.
... a review was under way by the Ministry of Food and Drug Safety, together with an independent advisory board, on whether to use the AstraZeneca vaccine for those over the age of 65.
“There is an insufficient number of test cases of elderly people in the clinical test data that have been submitted so we need a statistical review,” ministry official Kim Sang-bong told the briefing.
AstraZeneca denied media reports this week that its vaccine was not very effective for people over 65, saying a strong immune response to the vaccine had been shown in blood analysis of elderly trial participants.